secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0001193125-24-044511
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq says Finch is a 'public shell', seeks delisting; company appeals
-----------------------------------------------------------------------

- Nasdaq notified Finch on Feb 16, 2024 that it believes the company is a public shell and continued listing is unwarranted.
- Finch disagrees and has requested an appeal hearing, which automatically stays any suspension or delisting pending the hearing.
- No assurance that the appeal will succeed or that Finch can maintain listing compliance.
- Patent litigation trial vs. Rebiotix/Ferring reset from May 20 to Aug 5, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000119312524044511/0001193125-24-044511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000119312524044511/d788826d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-044511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer